Herbal Monograph
Chaga
Inonotus obliquus (Ach. ex Pers.) Pilat
Hymenochaetaceae
Potent birch-parasitic fungus prized for exceptional antioxidant capacity and...
Overview
Plant Description
Chaga (Inonotus obliquus) is a parasitic fungus that forms a distinctive sterile conk (sclerotium) on the trunks of living birch trees. It is not a true mushroom in the conventional sense -- the harvestable mass is a sclerotium, an irregular, densely compacted mass of mycelium and wood substrate, not a reproductive fruiting body. The external surface is deeply cracked, black, and charcoal-like in appearance (resembling burnt wood or a clinker), with the intense black color attributable to extraordinarily high concentrations of melanin pigment. When broken open, the interior reveals a rich amber to golden-brown color with a cork-like to woody texture. The conk grows slowly over 10-20 or more years, reaching sizes of 25-40 cm (10-16 inches) across and protruding 10-25 cm from the tree trunk, occasionally growing much larger. The mass can weigh 2-15 kg. The true fruiting body of Inonotus obliquus is rarely observed; it forms as a resupinate (flat, crust-like) structure beneath the bark of dead trees after the host has died, producing basidiospores for reproduction. The sclerotium induces white heart rot in the host birch tree and eventually contributes to the death of the tree over decades.
Habitat
Primarily parasitic on birch trees (Betula spp.), especially Betula pendula (silver birch) and Betula pubescens (downy birch) in Europe and Russia, and Betula alleghaniensis (yellow birch) in North America. Less commonly found on alder (Alnus spp.), beech (Fagus spp.), oak (Quercus spp.), and hornbeam (Carpinus spp.), though birch-derived material is strongly preferred for medicinal use due to the birch-specific compound betulinic acid. Thrives in cold climatic regions with harsh winters. Found in mature boreal and temperate forests, typically at latitudes between 45 degrees and 65 degrees N. Prefers living trees that are at least 40 years old.
Distribution
Circumboreal distribution across the Northern Hemisphere. Major populations in Russia (Siberia, Urals, Far East -- Russia accounts for the majority of global wild harvest), Scandinavia (Finland, Sweden, Norway), the Baltic states (Estonia, Latvia, Lithuania), Poland, Belarus, Ukraine, northern China, northern Japan (Hokkaido), Korea, and across northern North America (Canada, northern United States including Maine, Minnesota, Michigan, Wisconsin, Vermont, New Hampshire). Finland and Russia are historically the most important sources of wild-harvested chaga.
Parts Used
Sclerotium (sterile conk)
Preferred: Dried sclerotium chunks for decoction; powdered sclerotium for capsules or extraction; hydroethanolic tincture (dual extraction); standardized hot-water or dual extract
The irregular black mass (sclerotium) harvested from living birch trees is the medicinal part. This is NOT a fruiting body -- it is a compact mass of fungal mycelium intergrown with birch wood and bark substrate, accumulated over years of parasitic growth. The black exterior (epidermis) is particularly rich in melanin and polyphenolic compounds, while the amber interior contains higher concentrations of polysaccharides and triterpenoids. Both layers contribute to the therapeutic profile and are used together in traditional preparations. The sclerotium contains compounds derived from both the fungus itself (polysaccharides, triterpenoids, SOD) and from the birch host (betulin, betulinic acid), making wild-harvested birch chaga unique compared to cultivated mycelial products.
Key Constituents
Polysaccharides (beta-glucans)
Polysaccharides, particularly beta-D-glucans, are considered the primary immunomodulatory constituents of chaga. They activate both innate and adaptive immune pathways. Hot-water extraction is the traditional and preferred method for extracting these compounds, as they are not soluble in ethanol. The beta-glucan content and profile are key quality markers for chaga preparations. In vitro and in vivo studies demonstrate that chaga polysaccharides enhance macrophage phagocytosis, stimulate cytokine production (IL-6, TNF-alpha, NO), and modulate T-cell and NK-cell activity.
Triterpenoids (lanostane-type)
Triterpenoids are the second major class of bioactive compounds in chaga, primarily responsible for anti-inflammatory and cytotoxic activities. They are extracted by ethanol or ethyl acetate (not efficiently by water alone), which is why dual extraction (hot water + ethanol) is recommended for full-spectrum preparations. The combination of fungal-derived lanostane triterpenoids (inotodiol, inonotusols) and birch-derived lupane triterpenoids (betulinic acid, betulin) creates a unique phytochemical profile not replicable in cultivated mycelium.
Melanin complex
The melanin complex is unique to the chaga sclerotium and is not produced in significant quantities by cultured mycelium. It contributes substantially to the exceptional antioxidant capacity of chaga extracts. Historical use in Russian folk medicine specifically noted the importance of the black outer layer. The melanin exhibits genoprotective activity, protecting DNA from oxidative damage. Its capacity to chelate heavy metals and scavenge a broad spectrum of free radicals (superoxide, hydroxyl, DPPH) is well documented in vitro.
Polyphenols and hispidin derivatives
Polyphenolic compounds, particularly hispidin and related styrylpyrones, are characteristic of the Hymenochaetaceae family and contribute to the antioxidant, anti-inflammatory, and potentially anti-diabetic effects of chaga. They are distinct from the melanin fraction but act synergistically as part of the overall antioxidant defense system.
Enzymes and small molecules
The exceptionally high SOD content of chaga is frequently cited as a distinguishing feature. SOD is a critical endogenous antioxidant enzyme and its abundance in chaga may contribute to the observed antioxidant and cytoprotective effects. However, oral bioavailability of exogenous SOD is debated, as enzymatic proteins may be degraded in the GI tract. Oxalic acid content is a safety-relevant constituent that must be considered with heavy, chronic use.
Herbal Actions
Modulates and balances immune function
Beta-D-glucans (1,3/1,6) activate innate immune cells via dectin-1 and TLR2 receptor pathways, stimulating macrophage phagocytosis, NK cell activity, and cytokine production. Chaga polysaccharides have demonstrated both immunostimulatory effects (enhancing immune response in immunocompromised states) and immunoregulatory effects (modulating excessive inflammatory cytokine release). In vivo studies show enhanced splenic lymphocyte proliferation and improved immune markers. This bidirectional modulation distinguishes the immunomodulating action from simple immunostimulation.
[3, 4, 5, 16]Prevents or slows oxidative damage to cells
Chaga possesses one of the highest oxygen radical absorbance capacity (ORAC) values recorded for any natural substance. Multiple mechanisms contribute: melanin complex provides potent free radical scavenging and heavy metal chelation; SOD catalyzes superoxide dismutation; polyphenols (hispidin, phenolic acids) quench reactive oxygen species; and triterpenoids modulate oxidative stress signaling pathways. The antioxidant activity is well documented in vitro using DPPH, ABTS, ORAC, and FRAP assays across multiple research groups and geographic sources.
[3, 5, 15, 16]Reduces inflammation
Multiple anti-inflammatory mechanisms demonstrated in vitro and in vivo: inotodiol and other lanostane triterpenoids inhibit NF-kB signaling and reduce COX-2 expression; ergosterol peroxide suppresses LPS-induced inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6); ethyl acetate fractions significantly inhibit NO production in RAW 264.7 macrophages; polysaccharides modulate excessive inflammatory cytokine release. Ma et al. (2013) demonstrated dose-dependent inhibition of NO production and NF-kB luciferase activity by petroleum ether and ethyl acetate fractions.
[3, 5, 6, 8]Protects the liver from damage
Aqueous and ethanolic extracts of chaga demonstrate hepatoprotective activity in animal models of chemically induced liver damage. Mechanisms include antioxidant protection of hepatocytes against oxidative stress, reduction of liver enzyme elevation (ALT, AST), and modulation of inflammatory pathways in liver tissue. Betulinic acid and inotodiol are considered key hepatoprotective constituents. Traditional Russian use for liver support is well documented. Glamoclija et al. (2015) confirmed hepatoprotective effects of both aqueous and ethanolic extracts from multiple geographic sources.
[1, 3, 5, 13]Helps the body adapt to stress and restore homeostasis
Chaga demonstrates adaptogenic-like properties in animal models, supporting resistance to physical and metabolic stressors. The immunomodulatory, antioxidant, and endocrine-supporting effects collectively contribute to a stress-buffering profile consistent with adaptogenic classification. Traditional Siberian use as a general tonic for endurance and resilience supports this action. However, formal adaptogenic classification criteria (Brekhman and Dardymov) have not been rigorously validated in human clinical trials for chaga specifically.
[1, 3, 4]Kills or inhibits the growth of microorganisms
Chaga extracts demonstrate broad-spectrum antimicrobial activity in vitro. Glamoclija et al. (2015) reported activity against Gram-positive bacteria (Staphylococcus aureus, Bacillus cereus, Listeria monocytogenes), Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa), and fungi (Candida spp.). The antimicrobial activity is attributed to triterpenoids, polyphenols, and melanin. Antiviral activity against influenza virus and other pathogens has been reported in preliminary studies. The clinical relevance of antimicrobial activity at achievable in vivo concentrations requires further study.
[3, 5, 18]Stimulates digestive secretions via bitter taste receptors
Chaga decoction has a distinctive bitter, earthy taste with vanillin-like undertones. The bitter quality is contributed by triterpenoid compounds (inotodiol, betulinic acid) and may stimulate digestive secretions via bitter taste receptor activation. Traditional use included support for gastric conditions, consistent with the bitter digestive-stimulating action.
[1, 13]Lowers blood pressure
Preliminary evidence suggests chaga extracts may have modest antihypertensive effects through antioxidant-mediated vascular protection and potential ACE inhibitory activity. Animal studies have shown reductions in blood pressure markers. Clinical significance in humans has not been established.
[3, 13]Therapeutic Indications
Immune System
Immune system support and modulation
Beta-glucan polysaccharides from chaga activate innate immune pathways (macrophages, NK cells, dendritic cells) via pattern recognition receptors (dectin-1, TLR2, CR3). In vivo animal studies demonstrate enhanced splenic lymphocyte proliferation, increased macrophage phagocytic activity, and improved immune markers in immunocompromised models. Multiple in vitro studies confirm dose-dependent immunomodulatory effects. The bidirectional modulating activity (stimulating underactive immunity while calming excessive inflammatory responses) is a key therapeutic feature. Human clinical data is limited but the mechanism of action via well-characterized beta-glucan receptors is well established across beta-glucan-containing fungi.
[3, 4, 11, 16]Supportive care during conventional cancer treatment (adjunctive)
Chaga extracts and isolated compounds (betulinic acid, inotodiol, polysaccharides) demonstrate cytotoxic activity against multiple cancer cell lines in vitro, including breast, lung, colon, prostate, liver, and melanoma. Betulinic acid induces apoptosis via the mitochondrial pathway selectively in tumor cells. Polysaccharides may support immune surveillance. Zhao & Zheng (2021) reviewed the antitumoral potential of chaga metabolites. Song et al. (2013) summarized anticancer mechanisms. In Russia, a chaga extract preparation called Befungin has been used as a supportive treatment in oncology since the 1950s. However, clinical evidence from controlled human trials is extremely limited, and chaga should NOT be used as a replacement for conventional cancer treatment.
[1, 6, 15, 17]Digestive System
Gastritis and gastric ulcers (supportive)
One of the oldest and most consistently documented traditional uses of chaga in Russian folk medicine is for gastrointestinal complaints, particularly gastritis and peptic ulcers. The Russian pharmacopoeia preparation Befungin was approved specifically for chronic gastritis. Anti-inflammatory triterpenoids and polysaccharides may protect gastric mucosa from inflammatory damage. In vivo animal studies support gastroprotective effects. Zhong et al. (2009) noted chaga's documented use for GI diseases in traditional Chinese and Russian medicine.
[1, 13, 17]Inflammatory bowel conditions (supportive)
Chaga polysaccharides demonstrated intestinal barrier protection and anti-inflammatory effects in animal models of intestinal inflammation. Su et al. (2022) showed that chaga polysaccharides ameliorated intestinal barrier dysfunction in type 2 diabetic mice, attenuating pathological changes and modulating gut microbiota composition. These findings suggest potential for supporting intestinal health, though human clinical data is lacking.
[3, 9]Hepatobiliary System
Liver protection and support
Hepatoprotective effects are among the best-documented pharmacological activities of chaga. In vivo studies demonstrate protection against chemically induced liver damage (CCl4, acetaminophen) with reduction of elevated liver enzymes (ALT, AST) and histopathological improvement. The mechanism involves antioxidant protection of hepatocytes, anti-inflammatory modulation, and possibly enhanced hepatic detoxification enzyme activity. Both aqueous extracts (polysaccharide-rich) and ethanolic extracts (triterpenoid-rich) demonstrate hepatoprotective activity. Glamoclija et al. (2015) confirmed hepatoprotective effects across specimens from Finland, Russia, and Thailand.
[3, 5, 13]Endocrine System
Blood glucose regulation support (type 2 diabetes, adjunctive)
Animal studies demonstrate hypoglycemic effects of chaga extracts in alloxan- and streptozotocin-induced diabetic models. Lu et al. (2010) found that the ethyl acetate fraction significantly decreased blood glucose, improved serum insulin levels, and enhanced liver glycogen in diabetic mice. The polysaccharide fraction also demonstrated blood glucose-lowering effects in diabetic animal models. Hispidin and related polyphenols may contribute to anti-diabetic effects via inhibition of advanced glycation end-product (AGE) formation and alpha-glucosidase inhibition. Clinical trials in humans are needed.
[3, 7, 13]Skin / Integumentary
Oxidative skin damage and aging (preliminary)
The exceptional antioxidant capacity of chaga, driven by its melanin complex, polyphenols, and SOD content, has attracted interest for dermatological applications. Melanin provides UV-protective and free radical scavenging properties relevant to skin aging. Paterska et al. (2024) included chaga among medicinal mushrooms with potential cosmetical anti-aging applications. However, clinical studies on topical or internal use for skin conditions are lacking.
[3, 19]Cardiovascular System
Cardiovascular risk factor modification (preliminary)
Animal studies suggest chaga extracts may modulate cardiovascular risk factors including oxidative stress, lipid levels, and blood pressure. Antioxidant protection against LDL oxidation and endothelial damage may contribute to vascular health. Zhong et al. (2009) noted chaga's traditional use and preliminary research for cardiovascular disease. Clinical human data is insufficient to support a specific cardiovascular indication.
[3, 13]Nervous System
Neuroinflammation and neuroprotection (preliminary)
Kou et al. (2021) identified polyoxygenated lanostanoids from chaga that significantly inhibited NO production in LPS-stimulated BV-2 microglial cells, suggesting anti-neuroinflammatory potential. Wei et al. (2022) identified triterpenoids acting as acetylcholinesterase and butyrylcholinesterase inhibitors. Wang et al. (2023) demonstrated that chaga polysaccharides reduced amyloid aggregation and facilitated ubiquitin-proteasome system activity in a 3xTg-AD mouse model. These are early-stage findings requiring clinical validation.
[8, 10, 12]Energetics
Temperature
cool
Moisture
slightly dry
Taste
Tissue States
hot/excitation, damp/stagnation
In Western herbal energetics, chaga is generally classified as cool to neutral and slightly drying. Its cooling nature aligns with its affinity for conditions with signs of heat, inflammation, and oxidative stress. The bitter taste reflects its triterpenoid content and digestive-supporting properties, while the bland quality relates to the polysaccharide and melanin fractions. The slight dryness is consistent with its astringent-like tissue-toning quality. Chaga is considered appropriate for constitutions running hot and damp -- conditions of excess inflammation, metabolic heat, and stagnation. In traditional Russian and Siberian folk medicine, chaga was considered a general restorative and cooling remedy for 'internal heat' and digestive complaints. NOTE: Herbal energetics are interpretive frameworks within Western herbalism and are not standardized across all practitioners. Fungal medicines are not traditionally categorized in the same energetic frameworks as botanical herbs, and these classifications represent a modern adaptation.
Traditional Uses
Russian and Siberian folk medicine
- General health tonic for endurance and vitality in harsh climates
- Treatment of gastritis, gastric ulcers, and other GI disorders
- Supportive treatment for tumors and cancerous growths
- Liver and spleen disorders
- Cardiovascular support and blood purification
- Pain relief for internal organs
- Parasitic infections (anti-helminthic folk use)
- Tea substitute consumed daily for general health maintenance
"Chaga has been used in Russian folk medicine since at least the 16th century, with documented use extending back centuries in Siberian and Ural mountain communities. The 12th-century Russian ruler Vladimir Monomakh allegedly used chaga to treat lip cancer. In 1858, Russian physician Froben first described the medical use of chaga. The State Pharmacological Committee of the USSR Ministry of Health approved a chaga extract (Befungin) in the 1950s for the treatment of gastritis, gastric ulcers, and as a symptomatic remedy in oncology. Alexander Solzhenitsyn referenced chaga's anticancer folk reputation in his novel 'Cancer Ward' (1968), bringing international attention to this traditional remedy."
Finnish and Nordic folk medicine
- Brewed as a daily health-promoting tea (simmered for hours)
- Treatment of stomach complaints and digestive disorders
- General tonic for cold-weather resilience
- Topical application of decoction for skin conditions
- Support for tuberculosis and respiratory conditions
"In Finland (where chaga is known as 'pakurikaaapa' or 'tikkatee') and across Scandinavian countries, chaga has been used as a folk remedy and daily beverage since at least the 16th-17th centuries. Finnish and Sami people traditionally prepared a strong decoction by simmering dried chaga chunks in water for extended periods. The practice of drinking chaga tea as a general health tonic persists in rural Finnish and Nordic communities."
Traditional Chinese medicine and East Asian use
- Classified as a qi-tonifying agent with bitter, neutral properties
- Support for liver and spleen function
- Treatment of digestive disorders and gastric complaints
- Cancer prevention and supportive therapy
- Regulation of blood sugar
"In northern China, particularly in the Changbai mountain region, chaga (known in Chinese as baihua rong or huashu rong) has been used as a traditional medicinal fungus. It appears in traditional herbals for its tonic and anti-tumor properties. In Japan (where it is known as kabanoanatake), chaga has been used in Ainu traditional medicine. Korean traditional medicine also includes references to chaga for digestive and immune support."
Indigenous North American traditions
- Ojibwa and Cree peoples used birch conk preparations for various ailments
- Preparation as a tea for digestive complaints
- Topical use of powdered conk for treating skin conditions and as a styptic
"Several First Nations peoples in the boreal regions of North America have documented traditional use of birch-associated fungi including chaga. The Ojibwa (Anishinaabe) and Cree peoples are reported to have used chaga preparations, though detailed ethnobotanical documentation is limited compared to Russian sources."
Modern Research
Comprehensive review of chaga bioactive compounds and pharmacological potential
Systematic review and compilation of published research on Inonotus obliquus covering chemical characterization, biological activities, and traditional applications. Identified major bioactive compound classes: polysaccharides (beta-glucans), triterpenoids (inotodiol, betulinic acid), melanins, and polyphenols (hispidin derivatives).
Findings: Summarized antioxidant, anti-inflammatory, immunomodulatory, anticancer, anti-diabetic, hepatoprotective, and antimicrobial activities supported by in vitro and in vivo evidence. Noted that the unique combination of fungal metabolites and birch-derived compounds in wild chaga creates a phytochemical profile not replicable in cultivated mycelium. Identified significant research gaps including the near-complete absence of controlled human clinical trials.
Limitations: Narrative review; no systematic search methodology described. Heterogeneity of extraction methods across reviewed studies. Most cited evidence is preclinical.
[3]
Chemical characterization and biological activity across geographic sources
Comparative analysis of aqueous and ethanolic extracts of Inonotus obliquus from Finland, Russia, and Thailand. Evaluated antioxidative, antimicrobial, antimutagenic, antigenotoxic, and hepatoprotective activities in vitro and in vivo.
Findings: All samples demonstrated significant antioxidant, antimicrobial, and hepatoprotective activity, though potency varied by geographic origin and extraction solvent. Ethanolic extracts were generally more potent for antimicrobial activity, while aqueous extracts showed stronger antioxidant effects in some assays. Finnish and Russian samples showed superior biological activity compared to Thai samples, likely reflecting differences in host tree species and growing conditions. Hepatoprotective effects were confirmed in HepG2 cell models.
Limitations: In vitro study design. Geographic comparisons limited to three samples per region. Specific compound quantification not performed for all bioactives. Clinical relevance of observed concentrations not established.
[5]
Anticancer mechanisms of Inonotus obliquus bioactive metabolites
Comprehensive review focused specifically on the antitumoral potential of I. obliquus metabolites, addressing polysaccharides, triterpenoids, polyphenols, and melanins with reference to their mechanisms of anticancer action.
Findings: Identified multiple anticancer mechanisms: (1) direct cytotoxicity via betulinic acid-mediated mitochondrial apoptosis, (2) anti-proliferative effects of inotodiol and ergosterol peroxide on various cancer cell lines, (3) immunostimulatory polysaccharides enhancing natural killer cell activity and macrophage-mediated tumor surveillance, (4) anti-angiogenic effects, and (5) anti-metastatic potential in animal models. Noted that chaga crude extracts from Russia and Baltic countries have been traditionally used to treat malignant tumors, gastritis, and gastric ulcers.
Limitations: Review of predominantly preclinical data. No controlled human clinical trials for cancer indications. In vitro cytotoxicity does not reliably predict in vivo efficacy. Heterogeneity of extraction methods and study quality across reviewed literature.
[17]
Anti-inflammatory and anticancer activities of extract fractions
Bioassay-guided fractionation of Inonotus obliquus to identify anti-inflammatory and anticancer constituents. Tested petroleum ether, ethyl acetate, n-butanol, and water fractions using NO production inhibition (RAW 264.7 macrophages), NF-kB luciferase activity, and cytotoxicity against human prostate cancer cells (PC3).
Findings: Petroleum ether and ethyl acetate fractions showed the most significant inhibition of NO production and NF-kB luciferase activity in macrophages. Bioactive triterpenoid and steroid compounds were identified including inotodiol, lanosterol, and ergosterol peroxide. Inotodiol showed significant dose-dependent anti-inflammatory and cytotoxic activity. The ethyl acetate fraction demonstrated the strongest cytotoxicity against PC3 prostate cancer cells.
Limitations: In vitro study. The observed cytotoxic concentrations may not be achievable in vivo through oral administration. Single cancer cell line tested. No selectivity index comparing cancer vs normal cells reported.
[6]
Hypoglycemic activity and phytochemical characterization of ethyl acetate fraction
Investigation of the hypoglycemic effect of the ethyl acetate fraction from Inonotus obliquus (EAFI) in alloxan-induced diabetic mice, with phytochemical identification of active constituents.
Findings: EAFI treatment led to significant decrease in blood glucose levels (P < 0.05) in alloxan-induced diabetic mice. It significantly improved serum insulin levels and enhanced liver glycogen content. The fraction also improved body weight recovery. Phytochemical analysis identified several active triterpenoid compounds. The results support the traditional use of chaga for diabetes-related conditions.
Limitations: Animal model (mice) with chemically induced diabetes, not reflecting the complex pathophysiology of human type 2 diabetes. Single-dose study design. No comparison with standard antidiabetic medication. EAFI is a semi-purified fraction, not a whole chaga preparation.
[7]
Anti-neuroinflammatory polyoxygenated lanostanoids
Chemical investigation of Inonotus obliquus leading to isolation of seven undescribed lanostane-type triterpenoids (inonotusols H-N). Anti-neuroinflammatory activity assessed in LPS-stimulated BV-2 microglial cells.
Findings: All seven new lanostanoids remarkably inhibited NO production in LPS-stimulated BV-2 microglial cells in a dose-dependent manner. Several compounds were more potent than the positive control indomethacin. The findings suggest chaga-derived triterpenoids may have neuroprotective potential through anti-neuroinflammatory mechanisms.
Limitations: In vitro study using a single microglial cell line. Blood-brain barrier penetration of these compounds has not been established. Concentrations used may not be achievable systemically through oral administration. No in vivo validation.
[8]
Chaga polysaccharide effects on intestinal barrier in diabetic mice
Investigation of a homogeneous polysaccharide from Inonotus obliquus (designated IN) and its protective effect on intestinal barrier function in type 2 diabetic mice.
Findings: IN (Mw 373 kDa) attenuated body weight loss and alleviated pathological changes in intestinal tissue of diabetic mice. It improved intestinal barrier function by upregulating tight junction proteins (ZO-1, occludin, claudin-1) and mucin-2 expression. IN also modulated gut microbiota composition, increasing beneficial Lactobacillus and Bifidobacterium populations while decreasing pathogenic taxa. The results suggest that chaga polysaccharides may benefit diabetic intestinal complications through gut barrier and microbiome modulation.
Limitations: Animal model (type 2 diabetic mice). Isolated polysaccharide fraction, not whole chaga extract. Short study duration. No human clinical data available for comparison.
[9]
Triterpenoids as cholinesterase inhibitors (Alzheimer's disease relevance)
Phytochemical investigation of triterpenoids from Inonotus obliquus and evaluation of their inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).
Findings: Fourteen triterpenoids were identified, including four undescribed compounds and two pairs of undescribed phenolic enantiomers. Several lanostane-type triterpenoids demonstrated bivalent and dual inhibitory activity against both AChE and BChE, enzymes implicated in the pathology of Alzheimer's disease. The findings suggest potential for chaga-derived compounds in neurodegenerative disease research.
Limitations: In vitro enzyme inhibition study. No cell-based or in vivo studies conducted. Blood-brain barrier penetration not assessed. Isolated pure compounds tested, not whole chaga extracts.
[10]
Chemical diversity and submerged culture strategies
Review of biologically active metabolites in wild chaga sclerotia and comparison with submerged culture (liquid fermentation) approaches to produce chaga mycelium and metabolites.
Findings: Documented the extensive chemical diversity of wild chaga sclerotia, including polysaccharides, lanostane triterpenoids, melanins, hispidin derivatives, and birch-derived triterpenes. Noted that submerged culture can produce mycelial biomass with some bioactive metabolites, but the sclerotium-specific metabolite profile (including betulinic acid, complex melanin, and full triterpenoid spectrum) is not fully replicable in cultured systems. As early as the 16th century, chaga was used as an effective folk medicine in Russia and Northern Europe.
Limitations: Review article covering diverse studies with varying methodologies. Does not include direct experimental comparison between wild and cultured products. Quality metrics for cultured products are not standardized.
[16]
Immunomodulatory effects of chaga polysaccharides in infected splenocytes
Investigation of the immunomodulatory effects of Inonotus obliquus polysaccharides (IOP) on mouse splenic lymphocytes under conditions of pathogen-induced inflammatory stress.
Findings: IOP significantly decreased the over-release of pro-inflammatory cytokines (IL-1beta, IL-4, IL-6, IFN-gamma, TNF-alpha) from pathogen-stimulated splenic lymphocytes. The results demonstrate that chaga polysaccharides can inhibit excessive inflammatory responses while maintaining baseline immune function, supporting the immunomodulating (rather than purely immunostimulant) classification.
Limitations: In vitro study using mouse splenocytes. Single pathogen challenge model. Does not establish in vivo immunomodulatory effects at oral doses achievable in humans.
[11]
Preparations & Dosage
Decoction
Strength: 10-15 g dried chaga per 1 L water; approximately 1:100 ratio
Break dried chaga sclerotium into small chunks (2-5 cm) or use coarse powder. Add 10-15 g of dried chaga to 1 liter (approximately 4 cups) of water. Bring to a gentle simmer (not a rolling boil) and maintain at low simmer for 1-3 hours. Longer simmering times (up to 4-6 hours) are traditional and may extract more polysaccharides and melanin. Strain through a fine mesh sieve. The resulting liquid should be a deep brown to black color. The same chunks can be re-simmered 2-3 times until the liquid becomes pale.
200-400 mL (approximately 1-2 cups) of decoction, 1-3 times daily
1-3 times daily. May be consumed daily as a health tonic.
Traditional use supports daily consumption for extended periods (weeks to months). Periodic breaks (e.g., 1-2 weeks off every 2-3 months) are prudent given limited long-term safety data.
Not well-established. Not traditionally used in children. If used for older children (>12 years), use half the adult dose and consult a qualified practitioner.
Decoction is the traditional and most common preparation method for chaga. Prolonged simmering is necessary to extract the water-soluble polysaccharides (beta-glucans) and melanin, which are the primary immunomodulatory and antioxidant compounds. This preparation does NOT efficiently extract the ethanol-soluble triterpenoids (inotodiol, betulinic acid). For a full-spectrum preparation, combine decoction with tincture (dual extraction approach). Do not boil vigorously, as excessive heat may degrade some bioactive compounds. The decoction has a mild, earthy, slightly bitter flavor with vanilla-like notes.
Tincture
Strength: 1:5, 40-60% ethanol (dried sclerotium)
Grind dried chaga sclerotium to a coarse powder. Macerate in 40-60% ethanol at a ratio of 1:5 (dried chaga to menstruum). Seal tightly and store in a cool, dark place for 4-6 weeks, agitating daily. Press and filter. For a dual-extraction tincture: prepare the tincture first, then decoct the marc (spent material) in water for 2-4 hours, concentrate the decoction, and combine with the filtered tincture.
2-5 mL (40-100 drops) two to three times daily
Two to three times daily
May be used for extended periods. Reassess after 8-12 weeks.
Not recommended for children without professional guidance
Ethanolic extraction captures the lipophilic triterpenoid compounds (inotodiol, betulinic acid, ergosterol peroxide, lanosterol derivatives) that are not efficiently extracted by water alone. However, polysaccharides (beta-glucans) are not well-extracted in ethanol. For this reason, dual extraction (combining hydroethanolic tincture with hot-water decoction) is considered the gold standard for a full-spectrum chaga preparation containing both water-soluble and alcohol-soluble bioactives.
Capsule / Powder
Strength: Crude dried sclerotium powder, typically 400-500 mg per capsule
Dried chaga sclerotium finely ground to powder and encapsulated. Ideally from wild-harvested birch chaga. Look for products specifying beta-glucan content and/or betulinic acid content on the label. Whole sclerotium powder contains all constituent classes but bioavailability may vary compared to extracted forms.
1000-3000 mg dried chaga powder daily in divided doses (2-6 capsules of 500 mg)
Two to three times daily, taken with meals
May be used for extended periods with periodic breaks. Reassess after 8-12 weeks.
Not recommended for children without professional guidance
Powdered sclerotium retains all constituent classes, but the polysaccharides and triterpenoids may have reduced bioavailability compared to extracted preparations due to the extremely dense, woody matrix of the sclerotium. Quality varies significantly among commercial products. Key quality markers to look for: wild-harvested from birch trees, beta-glucan content quantified, grown in cold-climate regions (Russia, Finland, Canada). Be aware that some commercial 'chaga' products are made from cultivated mycelium on grain, which lacks betulinic acid, melanin, and the full triterpenoid profile of wild sclerotium.
Standardized Extract
Strength: Typical DER 8:1 to 15:1. Standardized to minimum 20-30% beta-glucans or 30-50% polysaccharides.
Dual-extraction (hot water + ethanol) concentrated extract, typically standardized to beta-glucan content (minimum 20-30%) and/or polysaccharide content. Available as powdered extract in capsules or as liquid concentrate. The dual-extraction process captures both water-soluble (polysaccharides, melanin) and ethanol-soluble (triterpenoids) bioactive compounds.
500-1500 mg standardized extract daily in divided doses, depending on product concentration and standardization. Follow manufacturer guidelines based on extract ratio.
One to three times daily
May be used for extended periods. Reassess therapeutic need periodically.
Not established for standardized extracts in children
Standardized dual extracts represent the most pharmacologically complete commercially available preparation. They combine the immunomodulatory beta-glucans (water-soluble) with the anti-inflammatory and cytotoxic triterpenoids (ethanol-soluble). Quality markers: wild-harvested birch chaga source, dual extraction confirmed, beta-glucan content verified by enzymatic assay (Megazyme method), absence of starch fillers (some products inflate 'polysaccharide' content with grain starch). The Russian preparation Befungin is a historical example of a standardized chaga extract used in clinical settings since the 1950s.
Infusion (Tea)
Strength: 5-10 g dried chaga powder per 500 mL water
A lighter preparation than a full decoction. Pour boiling water (500 mL) over 5-10 g of finely ground chaga powder. Cover and steep for 15-30 minutes. Strain. This preparation extracts more readily soluble compounds (some polysaccharides, polyphenols, melanin pigment) but is less thorough than a long-simmered decoction.
200-250 mL (1 cup) 2-3 times daily
2-3 times daily
May be used daily. Reassess periodically.
Not well-established for children
A practical everyday preparation, though a prolonged decoction (1-3 hours simmering) is generally preferred for maximum polysaccharide extraction. The infusion method is suitable for finely ground chaga powder and may extract sufficient bioactive compounds for a daily health tonic. The resulting tea has a mild, slightly bitter, earthy flavor. Sometimes combined with honey, ginger, or cinnamon for palatability.
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Although allergic reactions to chaga are rarely reported, individuals with known fungal allergies should exercise caution. Discontinue use immediately if signs of allergic reaction occur (rash, itching, respiratory difficulty).
In vitro studies suggest chaga extracts may inhibit platelet aggregation. While clinical bleeding events from chaga have not been reported, precautionary discontinuation 2 weeks before scheduled surgery is advisable. Individuals with active bleeding disorders should consult their healthcare provider before use.
Chaga contains significant oxalic acid content. A case report documented oxalate nephropathy in a 72-year-old Japanese woman who consumed chaga powder daily for 6 months for liver cancer. Individuals with impaired renal function, a history of calcium oxalate kidney stones, or hyperoxaluria should avoid chaga or use with extreme caution and medical supervision.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Warfarin, heparin, and other anticoagulants/antiplatelet agents (Anticoagulants/Antiplatelets) | theoretical | In vitro studies suggest chaga extracts may inhibit platelet aggregation. No specific mechanism fully elucidated. May theoretically potentiate anticoagulant effects and increase bleeding risk. |
| Insulin, metformin, sulfonylureas, and other hypoglycemic agents (Hypoglycemic agents) | theoretical | Animal studies demonstrate blood glucose-lowering effects of chaga extracts in diabetic models. Additive hypoglycemic effects are theoretically possible when combined with antidiabetic medications. |
| Cyclosporine, tacrolimus, mycophenolate, and other immunosuppressants (Immunosuppressants) | theoretical | Chaga's immunomodulatory beta-glucans stimulate innate immune cell activity. This could theoretically counteract the effects of immunosuppressive medications, potentially increasing the risk of transplant rejection or autoimmune disease flare. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
No human safety data exists for chaga use during pregnancy or lactation. No teratogenicity studies have been conducted. Given the immunomodulatory activity and lack of specific safety data, chaga should be avoided during pregnancy and breastfeeding unless recommended by a qualified healthcare provider. This is a precautionary recommendation due to data insufficiency rather than evidence of harm.
Adverse Effects
References
Monograph Sources
- [1] Shikov AN, Pozharitskaya ON, Makarov VG, Wagner H, Verpoorte R, Heinrich M. Medicinal plants of the Russian Pharmacopoeia; their history and applications. J Ethnopharmacol (2014) ; 154 : 481-536 . DOI: 10.1016/j.jep.2014.04.007 . PMID: 24742754
- [2] Balandaykin ME, Zmitrovich IV. Review on Chaga Medicinal Mushroom, Inonotus obliquus (Higher Basidiomycetes): Realm of Medicinal Applications and Approaches on Estimating its Resource Potential. Int J Med Mushrooms (2015) ; 17 : 95-104 . DOI: 10.1615/IntJMedMushrooms.v17.i2.10 . PMID: 25746615
- [3] Fordjour E, Manful CF, Javed R, Galagedara LW, Cuss CW, Cheema M, Thomas R. Chaga mushroom: a super-fungus with countless facets and untapped potential. Front Pharmacol (2023) ; 14 : 1273786 . DOI: 10.3389/fphar.2023.1273786 . PMID: 38116085
- [4] Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol (1999) ; 19 : 65-96 . PMID: 9987601
Clinical Studies
- [5] Glamoclija J, Ciric A, Nikolic M, Fernandes A, Barros L, Calhelha RC, Ferreira IC, Sokovic M, van Griensven LJ. Chemical characterization and biological activity of Chaga (Inonotus obliquus), a medicinal 'mushroom'. J Ethnopharmacol (2015) ; 162 : 323-332 . DOI: 10.1016/j.jep.2014.12.069 . PMID: 25576897
- [6] Ma L, Chen H, Dong P, Lu X. Anti-inflammatory and anticancer activities of extracts and compounds from the mushroom Inonotus obliquus. Food Chem (2013) ; 139 : 503-508 . DOI: 10.1016/j.foodchem.2013.01.030 . PMID: 23561137
- [7] Lu X, Chen H, Dong P, Fu L, Zhang X. Phytochemical characteristics and hypoglycaemic activity of fraction from mushroom Inonotus obliquus. J Sci Food Agric (2010) ; 90 : 276-280 . DOI: 10.1002/jsfa.3809 . PMID: 20355042
- [8] Kou RW, Han R, Gao YQ, Li D, Yin X, Gao JM. Anti-neuroinflammatory polyoxygenated lanostanoids from Chaga mushroom Inonotus obliquus. Phytochemistry (2021) ; 184 : 112647 . DOI: 10.1016/j.phytochem.2020.112647 . PMID: 33434790
- [9] Su L, Xin C, Yang J, Dong L, Mei H, Dai X, Wang Q. A polysaccharide from Inonotus obliquus ameliorates intestinal barrier dysfunction in mice with type 2 diabetes mellitus. Int J Biol Macromol (2022) ; 214 : 312-323 . DOI: 10.1016/j.ijbiomac.2022.06.071 . PMID: 35714869
- [10] Wei YM, Yang L, Wang H, Cai CH, Dai HF, Chen HP. Triterpenoids as bivalent and dual inhibitors of acetylcholinesterase/butyrylcholinesterase from the fruiting bodies of Inonotus obliquus. Phytochemistry (2022) ; 198 : 113182 . DOI: 10.1016/j.phytochem.2022.113182 . PMID: 35427650
- [11] Sang R, Sun F, Zhou H, Li L, Li T, Ding R, Tao M. Immunomodulatory effects of Inonotus obliquus polysaccharides. Immunopharmacol Immunotoxicol (2022) ; 44 : 204-214 . DOI: 10.1080/08923973.2021.2017453 . PMID: 34918603
- [12] Wang S, Dong K, Zhang J, Zhang Y, Liu B, Zhao L. Raw Inonotus obliquus polysaccharides ameliorate Alzheimer's disease pathology in 3xTg-AD mice. Nutr Res Pract (2023) ; 17 : 1128-1140 . DOI: 10.4162/nrp.2023.17.6.1128 . PMID: 38053824
Traditional Texts
- [13] Zhong XH, Ren K, Lu SJ, Yang SY, Sun DZ. Progress of research on Inonotus obliquus. Chin J Integr Med (2009) ; 15 : 156-160 . DOI: 10.1007/s11655-009-0156-2 . PMID: 19407959
- [14] Zjawiony JK. Biologically active compounds from Aphyllophorales (polypore) fungi. J Nat Prod (2004) ; 67 : 300-310 . PMID: 14987072
- [15] Song FQ, Liu Y, Kong XS, Chang W, Song G. Progress on understanding the anticancer mechanisms of medicinal mushroom: Inonotus obliquus. Asian Pac J Cancer Prev (2013) ; 14 : 1571-1578 . PMID: 23679238
Pharmacopeias & Reviews
- [16] Zheng W, Miao K, Liu Y, Zhao Y, Zhang M, Pan S, Dai Y. Chemical diversity of biologically active metabolites in the sclerotia of Inonotus obliquus and submerged culture strategies for up-regulating their production. Appl Microbiol Biotechnol (2010) ; 87 : 1237-1254 . DOI: 10.1007/s00253-010-2682-4 . PMID: 20532760
- [17] Zhao Y, Zheng W. Deciphering the antitumoral potential of the bioactive metabolites from medicinal mushroom Inonotus obliquus. J Ethnopharmacol (2021) ; 265 : 113321 . DOI: 10.1016/j.jep.2020.113321 . PMID: 32877719
- [18] Teplyakova TV, Ilyicheva TN, Kosogova TA, Baldanov SN. Medicinal Mushrooms against Influenza Viruses. Int J Med Mushrooms (2021) ; 23 : 1-11 . DOI: 10.1615/IntJMedMushrooms.2020037460 . PMID: 33639077
- [19] Paterska M, Czerny B, Cielecka-Piontek J. Macrofungal Extracts as a Source of Bioactive Compounds for Cosmetical Anti-Aging Therapy: A Comprehensive Review. Nutrients (2024) ; 16 : 2810 . DOI: 10.3390/nu16162810 . PMID: 39203946
Last updated: 2026-03-01 | Status: published
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.